Dr Schofield has been a Consultant Cardiologist at Papworth and Addenbrooke’s Hospitals, Cambridge, since 1989.  He has extensive experience in the investigation and treatment of patients with cardiovascular disease.
 
His sub-speciality interest is Interventional Cardiology, particularly coronary angioplasty / coronary artery stenting and using new minimally invasive techniques for treating mitral valve disease.
 
Dr Schofield holds a 'silver' National Clinical Excellence Award. He is the Training Programme Director for Cardiology Training within the East of England. He is a former secretary of the British Cardiac Society.
 

Specialist Clinical Interests

General Cardiology.
Interventional Cardiology / Coronary Rotablation.
Refractory Angina.
Percutaneous mitral valve repair.

Research Interests

Evaluation of new technologies.
New techniques for treating patients with refractory angina.
Development and Investigation of new devices to treat mitral valve regurgitation.

Clinical Outcomes

To view Dr Schofield's clinical outcomes, please click on this link. This will take you to the British Cardiovascular Intervention Society website which is not part of the Papworth Hospital website.

Education and Training

MBCHB (Honors) Manchester University
FRCP Fellow of Royal College of Physicians
MD Manchester University
FACC Fellow of American College of Cardiology
FESC Fellow of European Society of Cardiology

Current membership(s) of professional, national and regional bodies and university posts

British Cardiovascular Society
British Cardiovascular Intervention Society
Lecturer at University of Cambridge
Chairman Anglia Cardiac Network
Program Director of the East of England Cardiology Training

Recent and Important Publications

An open label single centre, randomised trial of spinal cord stimulation vs percutaneous  myocardial laser revascularisation in patients with refractory angina pectoris: the SPiRiT trial. European Heart Journal 2006; 27:1048-1053.
Proton NMR analysis of plasma is a weak predictor of coronary artery disease.  Nature Medicine 2006; 12:6:705-710.
Tamoxifen for the prevention of myocardial infarction in humans;pre-clinical and early clinical evidence.  Circulation 2005;112:3018-24.